AI-generated analysis. Always verify with the original filing.
Coya Therapeutics announced the departure of Founder and Executive Chairman Dr. Howard Berman and the appointment of Mark H. Pavao as an independent director, effective April 1, 2026.
Dr. Howard Berman, the Company's Founder, resigned as Executive Chairman and from the Board effective April 1, 2026. The departure follows a planned CEO transition process initiated in November 2024, during which Dr. Berman moved to the Executive Chairman role. In connection with his departure, the Company entered into a Separation and General Release Agreement providing for a prorated 2026 bonus, COBRA premium coverage through March 2027, and extended vesting and exercise provisions for his stock options. Mark H. Pavao was appointed as an independent Class III Director to fill the resulting vacancy. Mr. Pavao possesses over 30 years of leadership experience in the global biopharmaceutical industry, having held senior roles at Biotech Value Advisors, R-Pharm US, and Bristol-Myers Squibb. He will be compensated with an option grant for 10,000 shares and standard director fees.
Event Type
Disclosure
Mandatory
Variant
8-K
. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure o
Financial Statements and Exhibits. (d) Exhibits. Exhibit No.: 10.1 | Description: Separation and Release Agreement, dated March 29, 2026. Exhibit No.: 99.1 | De
Dr. Howard Berman
Effective: 2026-04-01
Resigned from the Board and his position as Executive Chairman.
Mark H. Pavao
Effective: 2026-04-01
Appointed to fill vacancy created by Dr. Berman's resignation.